Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DQGF20
|
|||
| Drug Name |
ALKS 4230
|
|||
| Drug Type |
Protein
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 2 | [1] | |
| Company |
Alkermes
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04592653) A Study of ALKS 4230 (Nemvaleukin Alfa) on the Tumor Microenvironment (ARTISTRY-3). U.S. National Institutes of Health. | |||
| REF 2 | ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. J Immunother Cancer. 2020 Apr;8(1):e000673. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.